Liver function tests and lidocaine metabolism (MEGX test) during i.v. CMF therapy in breast cancer

Anti-Cancer Drugs

Volumn 7, Issue 8, 1996, Pages 846-850

  Rizzi, Viviana ^a   Cioschi, Beatrice ^a   Cartei, Giuseppe ^a   Bertolissi, Alessandra ^a   Tabaro, Gianna ^a   Marsilio, Pietro ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

breast cancer; chemotherapy; lidocaine; liver toxicity; MEGX

Indexed keywords

CYCLOPHOSPHAMIDE; DEETHYLLIDOCAINE; FLUOROURACIL; LIDOCAINE; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG METABOLISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION; LIVER TOXICITY; PRIORITY JOURNAL;

EID: 0029750662     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199611000-00005     Document Type: Article

References (34)

1. Oellerich M, Raude E. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem 1987; 25: 845-53.
2. Oellerich, Burdelski M, Ringe B, et al. Lignocaine metabolite formation as a measure of pretreatment liver function. Lancet 1989; 1: 640-2.
3. Cartei G, Cioschi B, Rizzi V, Tabaro G, Bertolissi A. II carico e.v. di lidocaina e la determinazione della monoetilglicinexilidide plasmatica (test MEGX) in epatologia e oncologia. Rivista Medica del Friuli 1996; 2: 21-30.
4. Boyes RN, Scott DB, Jebson PJ, Godman MJ, Julian DG. Pharmacokinetics of lidocaine in man. Clin Pharmacol Ther 1971; 12: 105-16.
5. Rowland M, Thompson PD, Guichard A. Disposition and kinetics of lidocaine in normal subjects. Ann NY Acad Sci 1971; 179: 383-97.
6. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 1989; 46: 521-7.
7. Schinella M, Guglielmi A, Veraldi GF, et al. Evaluation of the liver function of cirrhotic patients based on the formation of monoethylglycinexylidide (MEGX) from lidocaine. Eur J Clin Chem Clin Biochem 1993; 31: 553-7.
8. Oellerich M, Burdelski M, Lautz HU. Assessment of pretransplant prognosis in patients with cirrhosis. Transplantation 1991; 51: 801-6.
9. Huang YS, Lee SD, Deng JF, et al. Measuring lidocaine metabolite monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993; 19: 140-7.
10. Forte G, Rocco P, Costanzo A, et al. Monoethylglycinexylidide production as a measure in predicting hepatic histology. Ital J Gastroenterol 1994; 26: 159-62.
11. Oellerich M, Burdelski M, Lautz HU, et al. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Ther Drug Monit 1990; 12: 219-26.
12. Luketic VA, Shiftman ML, Fisher RA, et al. Hepatic lidocaine metabolism is useful in the selection of patients in need of liver transplantation. Transplant Proc 1993; 25: 1072-4.
13. Oellerich M, Hartmann H, Ringe B, et al. Assessment of prognosis in transplant candidates by use of the Pugh-Megx score. Transplant Proc 1993; 25: 1116-9.
14. Burdelski M, Oellerich M, Bornscheuer A, et al. Donor rating in human liver transplantation: correlation of oxygen consumption after revascularization with MEGX formation in donors. Transplant Proc 1989; 21: 2392-3.
15. Rossi SJ, Schroeder TJ, Vine WH, et al. Monoethylglycinexylidide formation in assessing pediatric donor liver function. Tber Drug Monit 1992; 14: 452-6.
16. Schroeder TJ, Pesce AJ, Ryckman FC, et al. Selection criteria for liver transplant donors. J Clin Lab Anal 1991; 5: 275-7.
17. Van Lente F, Bratush JR. Measurement of monoethylglycinexylidide (MEGX) as an index of donor liver function: a practical experience (abstract). THer Drug Monit 1993; 15: 147.
18. Oellerich M, Burdelski M, Beyrau R, et al. Lidocaine metabolite formation as a measure of early post-transplant liver function. Hepatology 1989; 10: 625.
19. Potter MJ, Balderson GA, Hickman PE, et al. The value of the donor MEGX test in predicting liver allograft recipient outcome. Transplantation 1994, 58: 524-6.
20. Oellerich M, Burdelski M, Ringe B, et al. Functional state of the donor liver and early outcome of transplantation. Transplant Proc 1991; 23: 1575-8.
21. Schroeder J, Wandel C, Bohrer H, et al. Lignocaine metabolite formation: an indicator for liver dysfunction and predictor of survival in surgical intensive care patients. Anaesthesia 1995; 50: 850 4
22. Cannizzaro R, Robieux I, Valentini M, et al. Liver function assessment by MEGX. Application to oncology. Ann NY Acad Sci 1996, 784: 486-90.
23. Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996; 59: 32-40.
24. Ménard DB, Gisselbrecht C, Marthy M, et al. Antineoplastic agents and the liver. Gastroenterology 1980; 78: 142-64.
25. Perry MC. Chemotherapeutic agents and hepatotoxicity. Semin Oncol 1992; 19: 551-65.
26. Rossi A, Bonadonna G, Valagussa P, Veronesi U. Multimodal treatment in operable breast cancer: five-year results of the CMF program. Br Med J 1981; 282: 1427-31.
27. Jaffe N, Traggis D. Toxicity of high-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) in osteogenic sarcoma. Cancer Chemother Rep 1975; 6: 31-6.
28. Podurgiel BJ, McGill DB, Ludwig J, Taylor WE Muller SA. Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin Proc 1973: 48: 787-92.
29. Bajetta E, Buzzoni R, Giardini R, Bonadonna G. Liver assessment in women receiving adjuvant CMF-chemotherapy. Tumori 1981; 67: 27-30.
30. Fazio M, Airoldi M, Bo L, et al. Hepatic and cardiac toxicity during CMF chemotherapy. Chemioterapia 1983; 2: 14-8.
31. Benowitz NL, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet 1978; 3: 177-201.
32. Reichen J. MEGX test in hepatology: the long-sought ultimate quantitative liver function test? J Hepatol 1993; 19: 4-7.
33. Huet PM, Villenueve JP. Determinants of drug disposition in patients with cirrhosis. Hepatology 1983; 3: 919-28.
34. Chang TKH, Waxman DJ. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5-α-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. Cancer Res 1993; 53: 2490-7.